Home › News › Market

Mankind Pharma In-Licenses Ensartinib from Betta Pharmaceuticals for India

Mankind Pharma In-Licenses Ensartinib from Betta Pharmaceuticals for India

Mankind Pharma has entered into an in-licensing agreement with China-based Betta Pharmaceuticals to develop, manufacture, register and commercialise Ensartinib in India. The drug is approved by the US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA) for adults with Anaplastic Lymphoma Kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.

Under the agreement, Mankind Pharma will make an upfront payment to Betta Pharmaceuticals, along with potential development and sales milestone payments and royalties based on annual net sales of Ensartinib in India. The company will receive exclusive rights for the drug in the Indian market, subject to the terms of the agreement.

Ensartinib is a targeted therapy that inhibits Anaplastic Lymphoma Kinase (ALK), a protein involved in cancer cell growth in certain patients with NSCLC. ALK-positive lung cancer is a distinct molecular subtype of the disease for which targeted treatments are used.

Atish Majumdar, Senior President of Mankind Pharma, said the agreement would strengthen the company's oncology portfolio and support its expansion into specialised therapies through strategic partnerships.

Shizhe Ding, Chairman Assistant and Head of Business Development at Betta Pharmaceuticals, said the collaboration would support the expansion of Ensartinib's reach and provide access to the targeted treatment for a wider patient population.

The agreement is part of Mankind Pharma's efforts to expand its oncology portfolio through external collaborations alongside its existing capabilities. The introduction of Ensartinib in India will be subject to applicable regulatory approvals and the completion of commercial and operational requirements. Further details of the agreement are expected to be announced in due course.

More news about: market | Published by News Bureau | November - 17 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members